Stephen Bloch Sells 100,000 Shares of Liquidia (NASDAQ:LQDA) Stock

Liquidia Corporation (NASDAQ:LQDA) Director Stephen Bloch sold 100,000 shares of Liquidia stock in a transaction on Monday, June 22nd. The shares were sold at an average price of $75.74, for a total transaction of $7,574,000.00. Following the completion of the sale, the director directly owned 880,073 shares in the company, valued at $66,656,729.02. This represents a 10.20% decrease in their position. The transaction was disclosed in a document filed with the SEC, which can be accessed through the SEC website.

Liquidia Stock Performance

NASDAQ:LQDA opened at $76.92 on Friday. The company has a debt-to-equity ratio of 1.18, a quick ratio of 2.03 and a current ratio of 2.22. The company has a fifty day moving average of $56.01 and a two-hundred day moving average of $43.50. The stock has a market capitalization of $6.84 billion, a PE ratio of 549.47 and a beta of 0.58. Liquidia Corporation has a fifty-two week low of $11.85 and a fifty-two week high of $78.25.

Liquidia (NASDAQ:LQDA) last posted its quarterly earnings data on Monday, May 11th. The company reported $0.52 earnings per share (EPS) for the quarter, beating the consensus estimate of $0.41 by $0.11. The business had revenue of $132.87 million for the quarter, compared to the consensus estimate of $119.44 million. Liquidia had a net margin of 7.74% and a return on equity of 46.82%. The firm’s revenue was up 4187.1% on a year-over-year basis. As a group, research analysts forecast that Liquidia Corporation will post 2.97 earnings per share for the current fiscal year.

Wall Street Analysts Forecast Growth

Several equities research analysts have commented on LQDA shares. Jefferies Financial Group reiterated a “buy” rating and set a $60.00 price objective on shares of Liquidia in a research note on Monday, May 11th. Oppenheimer set a $75.00 target price on Liquidia in a research report on Friday, June 5th. Wells Fargo & Company lifted their price target on Liquidia from $51.00 to $62.00 and gave the stock an “overweight” rating in a research note on Tuesday, May 12th. Weiss Ratings reiterated a “sell (d-)” rating on shares of Liquidia in a research report on Tuesday, April 21st. Finally, BTIG Research increased their price objective on Liquidia from $59.00 to $109.00 and gave the company a “buy” rating in a research note on Monday. Three analysts have rated the stock with a Strong Buy rating, five have assigned a Buy rating and two have given a Sell rating to the company’s stock. According to data from MarketBeat.com, the company has an average rating of “Moderate Buy” and an average price target of $67.43.

Institutional Trading of Liquidia

A number of hedge funds have recently bought and sold shares of LQDA. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. lifted its stake in Liquidia by 4.7% in the 1st quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 37,681 shares of the company’s stock worth $556,000 after purchasing an additional 1,700 shares in the last quarter. Goldman Sachs Group Inc. increased its holdings in shares of Liquidia by 10.7% in the first quarter. Goldman Sachs Group Inc. now owns 861,231 shares of the company’s stock valued at $12,703,000 after purchasing an additional 82,955 shares during the last quarter. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC lifted its position in Liquidia by 15.2% during the first quarter. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC now owns 121,756 shares of the company’s stock worth $1,796,000 after buying an additional 16,022 shares in the last quarter. Creative Planning lifted its position in Liquidia by 40.7% during the second quarter. Creative Planning now owns 26,840 shares of the company’s stock worth $334,000 after buying an additional 7,765 shares in the last quarter. Finally, Legal & General Group Plc boosted its stake in Liquidia by 13.4% during the second quarter. Legal & General Group Plc now owns 94,152 shares of the company’s stock worth $1,174,000 after buying an additional 11,111 shares during the last quarter. Institutional investors and hedge funds own 64.54% of the company’s stock.

Liquidia Company Profile

Liquidia Technologies, Inc is a clinical-stage biopharmaceutical company headquartered in Research Triangle Park, North Carolina. The company leverages its proprietary PRINT® (Particle Replication In Non-wetting Templates) platform to engineer precisely shaped and sized drug particles, with the goal of improving delivery, efficacy and safety profiles. By controlling particle characteristics at the nanoscale, Liquidia seeks to enhance respiratory and other therapies that depend on targeted delivery.

The company’s lead product candidate, LIQ861, is a dry powder formulation of treprostinil designed for inhalation in patients with pulmonary arterial hypertension (PAH).